ABOUT CYTIVA
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery.
We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more.
PRODUCT VIDEOS
FEATURED PRODUCTS
-
Research Use Only (RUO) lipid nanoparticle (LNP) reagents to deliver RNA into hematopoietic stem cells (HSCs) for cell and gene therapy applications.
-
Off-the-shelf, research use only lipid nanoparticle (LNP) reagents to deliver RNA into T-cells.
-
Explore scalable and flexible single-use solutions from design to delivery that can help you overcome challenges throughout adeno-associated virus (AAV) manufacturing workflow.
-
Learn about a scalable, single-use platform with built-in automation and regulatory compliance that enables standardized manufacturing workflows for mRNA-LNP drug product production.
-
The NanoAssemblr® commercial formulation system is an automated, single-use system for the clinical and commercial production of lipid nanoparticles (LNPs) under cGMP conditions. Designed for efficient changeover and robust manufacturing processes, the system enables operational flexibility and standardized manufacturing of genomic medicines.
-
Discover a one-stop-shop for LNP technologies that provides access to expertise in formulation and analytics for successful outcomes for payload and target applications. Explore end-to-end biopharma services and systems.
-
By combining disruptive technology platforms with unparalleled genomic medicine development expertise, we're positioned to accelerate the development of LNP formulations and drug products.
-
Ignite simplifies the transition into clinical programs by incorporating these fundamental process steps for scale up in the earliest stages of pre-clinical development.
-
GenVoy-ILM™ T Cell Kit for mRNA, Ignite is an lipid nanoparticle (LNP) reagent mix optimized for the delivery of messenger RNA (mRNA) or Cas9 mRNA/sgRNA into activated human primary T cells.
-
With NxGen™ technology on the NanoAssemblr® Blaze™, important studies can be conducted efficiently with a process that mirrors a clinical scale implementation.
-
The GenVoy-ILM T Cell Kit for mRNA is optimized for the delivery of mRNA into activated primary human T cells using mRNA-LNPs formulated on the NanoAssemblr Spark instrument and cartridges.
-
Built on our revolutionary NxGen™ technology found in our NanoAssemblr® family of instruments, the NanoAssemblr® GMP System enables you to go from concept to clinic with speed and confidence.
-
GenVoy-ILM is a pre-optimized lipid mixture designed to encapsulate RNA – mRNA, gRNA, siRNA, miRNA, tRNA – in LNP.
-
The NanoAssemblr® Spark™ is ideal for nanomedicine formulation discovery and screening at microliter scales.
BROCHURES
- AAV Manufacturing Workflow
- Single-Use System For Clinical And Commercial Production Of LNPs
- Services For Advancing mRNA-LNPs From Bench To Clinic
- A Disruptive Technology Accelerating Drug Development
- GenVoy-ILM™ T Cell Kit For mRNA, Ignite™
- A Next-Generation Technology For The Power To Scale
- T Cell Kit For mRNA On NanoAssemblr Spark
- NanoAssemblr® GMP System: Power To Commercialize
- GenVoy-ILM™: Power To Explore
- NanoAssemblr® Spark™: Freedom To Discover
WEBINARS AND PODCASTS
APPLICATION NOTES
- Cell Culture Media Mixing In A Benchtop Single-Use Mixer
- Assessing Particle Generation In A Single-Use Mixing System
- A Transient Cell Line To Produce rAAV With Low-Level hcDNA Encapsidation
- How To Successfully Isolate Your T Cells
- Review Of Applications And Processes In Fixed-Bed Bioreactors
- Lentiviral Vector Production Using Single-Use Bioreactors
- Get Full Control Of Your T Cell Isolation
- Using Automated Spinoculation For CAR T Cell Lentiviral Transduction
- Standardize Scale-Up And Reduce Time To Market With Mixing Cartridges
- Understanding The Microfluidic Platforms For Scaling Nanoparticle Production
CONTACT INFORMATION
Cytiva
100 Results Way
Marlborough, MA 08855-1327
UNITED STATES
Phone: 800-526-3593
FEATURED ARTICLES
-
AAV vectors hold promise for gene therapy, but removing product-related impurities remains a challenge. Learn how cell line development and process optimization are advancing rAAV production.
-
Cell culture media isn’t one-size-fits-all. Learn how media composition, customization, and analytics can dramatically improve cell growth, productivity, and product quality for complex processes.
-
Scalable rAAV production is achievable with a transient cell line and optimized bioreactor setup, delivering high titers and reduced impurities, now validated at 200 L scale for commercial readiness.
-
Fixed-bed bioreactors simplify the scale-up of viral vector production. Discover a system that bridges development and manufacturing with data confirming consistent performance across scales.
-
Explore how powder media and sterile fluid handling can reduce contamination risk and improve efficiency in viral vector production, especially for HEK293-based AAV workflows.
-
Explore a high-yield, scalable process for hMSC-derived exosome production using fixed-bed bioreactors, with strong performance in purity, recovery, and biological activity.
-
Get a clear view of oligonucleotide development from synthesis to purification and filtration with practical insights to help you streamline workflows and stay ahead in the fight against disease.
-
Discover a practical guide to selecting filters for bioprocessing applications that are matched to product type, process stage, and performance needs such as virus filtration, clarification, and TFF.
-
Explore how lipid nanoparticles are revolutionizing cell therapy workflows to enable the precise delivery of mRNA and gene editing tools for next-generation treatments like CAR T and HSC therapies.
-
Viral vector-based gene therapies are expanding beyond rare diseases to treat larger populations. Discover how innovations in manufacturing are making these life-changing treatments more accessible.